Showing results (61-70 of 85) with videos related to
Sort By:
Pageof 9
Iscience|February 18, 2026
Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatmentVito W Rebecca, Min Xiao, Andrew Kossenkov, et al.Clinical and Translational Medicine|May 29, 2025
Responsiveness of different MET tumour alterations to type I and type II MET inhibitorsYonina R Murciano-Goroff, Valentina Foglizzo, Jason Chang, et al.Medrxiv : the Preprint Server for Health Sciences|December 23, 2024
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancerRajendra Kumar, Sheila Jonnatan, David E Sanin, et al.Cancer Cell|September 5, 2020
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast CancerAmaia Arruabarrena-Aristorena, Jesper L V Maag, Srushti Kittane, et al.Nature Medicine|August 14, 2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activationEmiliano Cocco, Alison M Schram, Amanda Kulick, et al.Cancer Research|November 21, 2025
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancerRajendra Kumar, Sheila Jonnatan, David E Sanin, et al.Cancer Discovery|January 10, 2020
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in LymphomaPatrizia Mondello, Saber Tadros, Matt Teater, et al.Science Signaling|October 11, 2018
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)Emiliano Cocco, F Javier Carmona, Pedram Razavi, et al.Nature Communications|November 18, 2018
Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractilityAna Angulo-Urarte, Pedro Casado, Sandra D Castillo, et al.Nature Genetics|January 15, 2020
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancerGuotai Xu, Sagar Chhangawala, Emiliano Cocco, et al.Pageof 9